Real-World Sequence Patterns of Novel Agents in CLL

[Jm954]

In real-world settings, most (nearly 93%) of patients with chronic lymphocytic leukemia (CLL) receive novel-agent therapies — and they receive these most often in the second-line setting, researchers reported in a poster on display during the 61st American Society of Hematology (ASH).

Data was analyzed for adult patients who initiated therapy for CLL/SLL in the relapsed/refractory setting after February 12, 2014. Treatment sequencing and clinical responses after treatment with BCL-2 inhibitor venetoclax, or novel agents in the B-cell receptor pathway inhibitor (BCRi) class such as ibrutinib, idelalisib, acalabrutinib, or another novel BCRi medication, were assessed.

Of the 355 patients available at the time of data analysis, 329 patients (93%) received a novel agent in at least 1 line of therapy. In addition, 120 patients (33.8%) received novel agents in 2 or more lines of therapy.

The most common BCRi-based therapy used was ibrutinib (85.3%), but 42.8% of these patients ended up needing another line of therapy. The most common subsequent therapy post-BCRi was venetoclax, which was typically administered as a second-line therapy (in 43% of patients who had a follow-up therapy). Venetoclax was used in at least 1 line of therapy in 101 patients (28.5%), and they were most likely to receive this drug in the 3rd-line setting.

More here: cancertherapyadvisor.com/ho...

Jackie

[Wroxham]

Thanks Jackie.

Sue

[virdieblue]

Jackie-

Have you seen anything about first line Ibrutinib users have Venetoclax added in? Rather than at relapse?

Virginia